Quantitative-Proteomic Comparison of Alpha and Beta Cells to Uncover Novel Targets for Lineage Reprogramming

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Choudhary, A., K. Hu He, P. Mertins, N. D. Udeshi, V. Dančík, D. Fomina-Yadlin, S. Kubicek, et al. 2014. “Quantitative-Proteomic Comparison of Alpha and Beta Cells to Uncover Novel Targets for Lineage Reprogramming.” PLoS ONE 9 (4): e95194. doi:10.1371/journal.pone.0095194. http://dx.doi.org/10.1371/journal.pone.0095194.

Published Version
doi:10.1371/journal.pone.0095194

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12152899

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Quantitative-Proteomic Comparison of Alpha and Beta Cells to Uncover Novel Targets for Lineage Reprogramming

Amit Choudhary1,2,9, Kaihui Hu He2,9, Philipp Mertins2, Namrata D. Udeshi2, Vlado Dančík2, Dina Fomina-Yadlin2,3na, Stefan Kubicek2nb, Paul A. Clemens2, Stuart L. Schreiber2,4,5, Steven A. Carr2, Bridget K. Wagner2n

1 Society of Fellows, Harvard University, Cambridge, Massachusetts, United States of America, 2 Center for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts, United States of America, 3 Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts, United States of America, 4 Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, United States of America, 5 Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America

Abstract

Type-1 diabetes (T1D) is an autoimmune disease in which insulin-secreting pancreatic beta cells are destroyed by the immune system. An emerging strategy to regenerate beta-cell mass is through transdifferentiation of pancreatic alpha cells to beta cells. We previously reported two small molecules, BRD7389 and GW8510, that induce insulin expression in a mouse alpha cell line and provide a glimpse into potential intermediate cell states in beta-cell reprogramming from alpha cells. These small-molecule studies suggested that inhibition of kinases in particular may induce the expression of several beta-cell markers in alpha cells. To identify potential lineage reprogramming protein targets, we compared the transcriptome, proteome, and phosphoproteome of alpha cells, beta cells, and compound-treated alpha cells. Our phosphoproteomic analysis indicated that two kinases, BRSK1 and CAMKK2, exhibit decreased phosphorylation in beta cells compared to alpha cells, and in compound-treated alpha cells compared to DMSO-treated alpha cells. Knock-down of these kinases in alpha cells resulted in expression of key beta-cell markers. These results provide evidence that perturbation of the kinome may be important for lineage reprogramming of alpha cells to beta cells.

Introduction

Type-1 diabetes (T1D) is a chronic autoimmune disease affecting 35 million patients worldwide. In T1D, insulin-secreting pancreatic beta cells are destroyed by autoreactive immune cells [1,2]. The most common treatment for T1D is daily injection of insulin; however, this treatment cannot always ensure optimal glucose homeostasis, leading to complications such as blindness, heart disease, limb amputation, and ultimately death [3]. Another therapeutic strategy involves transplantation of pancreatic islets [4] via infusion through the portal vein into the liver, but high cost [5], limited donor availability, and beta-cell toxicity [6,7] of immunosuppressive drugs severely restrict the use of this treatment protocol.

Since T1D is characterized by extreme loss of beta-cell mass, replenishing the beta-cell population by converting other pancreatic cell types, such as alpha cells, to beta cells may be a viable therapeutic strategy [8,9]. For example, lineage reprogramming of pancreatic alpha cells to beta cells by ectopic expression of transcription factor, Pax4, has been shown to restore normoglycemia in mouse models of diabetes [10]. An alternative, and potentially more therapeutically promising, approach for lineage reprogramming involves the use of small molecules. This approach, which we term chemical transdifferentiation [11], is potentially safer, as it does not require viral delivery, and offers greater dosage and temporal control. However, identification of proteins or pathways that can be targeted for chemical transdifferentiation requires knowledge of the similarities and differences in the molecular and physiological architecture of the initial state and the final, transdifferentiated state.

To gain such knowledge, we compared the transcriptomes and proteomes of alpha and beta cell lines. In addition to analyzing the proteome, and phosphoproteome of alpha cells, beta cells, and compound-treated alpha cells. Our phosphoproteomic analysis indicated that two kinases, BRSK1 and CAMKK2, exhibit decreased phosphorylation in beta cells compared to alpha cells, and in compound-treated alpha cells compared to DMSO-treated alpha cells. Knock-down of these kinases in alpha cells resulted in expression of key beta-cell markers. These results provide evidence that perturbation of the kinome may be important for lineage reprogramming of alpha cells to beta cells.
insulin expression in alpha cells (Figure S1 in File S1) [12,13].
BRD7389 and GW8510 inhibit several kinases, such as the RSK family and CDK2, suggesting that lineage reprogramming of alpha cells to insulin-producing cells may involve downregulation of specific phosphorylated proteins in alpha cells. We reasoned that a signature of such phosphorylated proteins would be its presence at a higher level in alpha cells compared to beta cells; further, BRD7389 and GW8510 treatment of alpha cells should lower the levels of such phosphorylated proteins, as the alpha cells progress towards an intermediary cell state. To identify phosphoryproteins with these signatures, we compared the phosphoproteomes of alpha and beta cell lines, and also examined the alterations in the phosphoproteomes of alpha cell line upon treatment with either BRD7389 or GW8510.

We identified two proteins, BR serine/threonine kinase 1 (Brsk1) and calcium/calmodulin-dependent protein kinase kinase 2 (Camkk2), which were each phosphorylated at higher levels for specific phosphosites in alpha cells as compared to those in beta cells. Moreover, both BRD7389 and GW8510 treatment of alpha cells led to decreased phosphorylation at these phosphosites for both proteins. Knock-down of either kinase was sufficient to induce mRNA and protein expression of beta-cell markers, including insulin, in alpha cells. Furthermore, inhibitors of Camkk2 pathway induced beta-cell markers in alpha cells. These studies highlight the importance of fully characterizing cell states using both genetic and proteomic technologies in developing a cellular reprogramming strategy.

Materials and Methods

Cell culture and reagents

Mouse pancreatic cell lines zTC1 and BTC3 were obtained from ATCC and cultured at 37°C and 5% CO2 in low-glucose (1 g/L) DMEM supplemented with 10% fetal bovine serum (Hyclone), 50 U/mL penicillin and 50 μg/mL streptomycin. Media was changed every 3–4 days. KN62 and KN93 were obtained from Sigma-Aldrich.

Media was changed every 3–4 days. KN62 and KN93 were used to measure OCR and ECAR over time and analyte concentrations were determined by adding the glucose analogue 2-deoxyglucose to determine glycolytic activity. Cell glycolytic activity was assessed by adding 10 mM 2-deoxyglucose at 34 min, while the maximum glycolytic activity was observed at 58 min. Cell mitochondrial respiration and glycolytic activity was assessed by adding 10 mM 2-deoxyglucose in the media. Cells were treated with 0.1% DMSO or 0.85 mM oligomycin at 55 min. Glycolytic reserve was determined by adding the glucose analogue 2-deoxyglucose into the media at 55 min. Cell mitochondrial respiration was assessed by adding 10 mM oligomycin into the media at 34 min, 1 μM of the ionophore CCCP, and a combination of 5 μM rotenone and 5 μM antimycin A at 76 min. zTC1 cells media contained 0.1% DMSO.

SILAC experiments

zTC1 and BTC3 cells were cultured in low-glucose (1 g/L) DMEM media (custom preparation from Caisson Laboratories) that was deficient in L-arginine and L-lysine. DMEM media was supplemented with 10% dialyzed FBS (Sigma-Aldrich), penicillin, streptomycin, glutamine, and either L-arginine (Arg 0) and L-lysine (Lys 0), L-arginine-15N-HCl (Arg 6) and L-lysine-4,4,5,5-d4 (Lys 4), or L-arginine-15N-HCl (Arg 10) and L-lysine-13C6,15N-HCl (Lys 8) (Sigma-Aldrich). To achieve >95% SILAC amino acid incorporation, cells were grown for 25 days. For alpha and beta cell comparison experiments, zTC1 cells were grown in heavy state (R10K8), BTC3 were grown in light state (R0K0), and the medium state (R6K4) contained a 1:1 mix of zTC1 and BTC3 cells. These experiments were completed in biological replicates with SILAC label swapping. After compound treatment, cells were washed with 1x PBS.

Cells were lysed at 4°C using a buffer containing 8 M urea, 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 2 μg/μl aprotinin (Sigma-Aldrich), 10 μg/μl leupeptin (Roche), 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 mM NaF, 2 mM Na2VO4, 50 ng/ml calycin A (Calbiochem), phosphatase inhibitor mixture 1 (1/100, Sigma) and phosphatase inhibitor mixture 2 (1/100, Sigma). Cellular lysates were spun down at 20,000×g at 4°C to remove insoluble material. Protein concentrations were determined using a bicinchoninic acid (BCA) protein assay (Pierce) and corresponding SILAC samples were combined in equal ratio. Approximately 3 mg of protein was used per SILAC state. Proteins were reduced with 5 mM dithiothreitol and subsequently alkylated with 10 mM iodoacetamide. Prior to digestion, samples were diluted 1:4 with 50 mM Tris-HCl pH 7.5. Proteins were digested with sequencing grade modified trypsin (Promega) using an enzyme-to-substrate ratio of 1:50 overnight at 25°C. Samples were acidified with 0.5% formic acid and subsequently desalted using a 500 μg tC18 Sep-Pak SPE cartridge (Waters) as previously described [16].

Non-phosphorylated and phosphorylated peptides were prepared as previously described [16]. Briefly, peptides were fractionated offline by strong cation exchange (SCX) chromatography on an Akta Purifier 10 system (GE Healthcare) using a polysulfoethyl A strong cation exchange (SCX) column from PolyLC (250×9.4 mm, 5 μm particle size, 200 A pore size). A 160 min gradient was utilized for the fractionation with using 7 mM KH2PO4, pH 2.65, 30% MeCN as solvent A and 7 mM KH2PO4, pH 2.65, 350 mM KCl, 30% MeCN as Solvent B. For proteome analyses 5% of each SCX fraction was aliquoted, and fractions were combined into 24 proteome samples that were subsequently desalted using a 500 μg cC18 Sep-Pak SPE cartridge (Waters) as previously described [16].

Peptides were then transeluted to the C18 portion of the StageTips. For phosphoproteome analysis, 95% of each SCX fraction was used, and the SCX fractions were combined into 12 phosphopeptide samples. All SCX fractions were subsequently desalted with reversed phase tC18 Sep-Pak columns. Phosphopeptide enrichment was completed using immobilized metal affinity chromatography (IMAC) as previously described [16]. Briefly, peptides were reconstituted in 200 μl of 40% MeCN/0.1% formic acid and incubated for with 10 μl of packed Phos-Select beads (Sigma) for 1 hr. Subsequently, IMAC beads were loaded on C18 StageTips, washed twice with 40% MeCN, 0.1% formic acid and once with 50 μl 1% formic acid. Phosphorylated peptides were then transtuted to the C18 portion of the StageTip by washing with 70 μl of 500 mM KH2PO4 (pH 7.0) three times. StageTips were then washed with 50 μl of 1% formic acid and peptides were eluted with 80 μl of 50% MeCN/0.1% formic acid and dried to completeness.
Peptide samples were reconstituted in 3% MeCN/1% formic acid analyzed by LC-MS/MS using an Agilent 1200 LC coupled online to an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific). Peptides were loaded onto a fused-silica capillary column (New Objective) packed in-house with 14 cm of C18 reversed phase media (3 μm ReproSil-Pur C18-AQ media, Dr. Maisch GmbH) and eluted into the mass spectrometer using a 70 min linear gradient (0.29%B/min) from 10% solvent A (0.1% formic acid) to 30% solvent B (0.1% formic acid/90% acetonitrile). The mass spectrometer was operated in the data dependent mode where an MS1 scan (R = 60 K) was acquired with the Orbitrap analyzer followed by acquisition of CID MS/MS scans with the iontrap analyzer on the top 16 most abundant ions. An MS1 ion target of 16106 ions and an MS2 target of 16104 ions were utilized for acquisition. The maximum ion time was set to 1 s for MS1 scans and set to 100 ms for MS/MS scans. The dynamic exclusion time was 120 s, the repeat count was set to 2, and the repeat duration was set to 20 s. Monoisotopic precursor selection and non-peptide monoisotopic recognition functions were enabled.

All proteome and phosphoproteome data were processed together using the MaxQuant software package v1.0.13.13 and searched against the International Protein Index protein sequence database (IPI version 3.70, mouse). For searching, the enzyme specificity was set to trypsin, the number of missed cleavages was set to 2, and the MS/MS tolerance was set to 0.5 Da. Oxidation of methionines, N-terminal protein acetylation, and phosphorylation of serines, threonines, and tyrosines were searched as variable modifications, while carbamidomethylation of cysteines was searched as a fixed modification. Peptides harboring oxidized methionines or N-terminal acetylations were used for protein quantification. Log2 SILAC ratios of βTC3 versus αTC1 cells followed a normal distribution that was fitted using least-squares regression. Mean and standard deviation values derived from the gaussian fit were used to calculate p-values.

The peptide and protein false discovery rate (FDR) was set to 0.01 and the site FDR was set to 1. Phosphosite localization was completed as described in Mertins et al. [18].

siRNA experiments

Mouse Bsk1 and Camkk2 Gene Solution siRNAs (Qiagen) were used to perform the gene knock-down experiments. Quantitect primer sets for each gene were used to determine gene expression. Mouse αTC1 cells were plated in 96-well Corning (3340) plates at 40,000 cells/well in 100 μL DMEM. 0.3 μL/well Lipofectamine RNAiMAX (Invitrogen) and Opti-MEM Media was used to transfect the mix of 4 different siRNA constructs into cells. Cells were incubated in transfection mix for 6 h at 37°C, before changing to fresh media. Cells were cultured for 3 days, followed by qPCR or immunohistochemistry. Statistical significance was determined using t-test.

shRNA experiments

The different shRNA lentiviruses were obtained from the RNAi Consortium (TRC; http://www.broadinstitute.org/raai/public/) in 96-well format, with approximately 108 viral particles/mL per
Hairpin identities are listed in Table S1 in File S1. Mouse αTC1 cells were plated in 96-well Corning (3340) plates at 40,000 cells/well in 100 μL standard culture media. The next day, polybrene was added to each well (6 μg/mL), and cells were spin-infected with 1 μL virus at 2,250 rpm for 30 min at 30°C. Media was changed 4 h later to fresh media. The next day, media containing 1 μg/mL puromycin was added. Puromycin-supplemented media was changed every 3 days. After 10 days in culture, cells were lysed and mRNA extracted using Qiagen RNeasy 96 Kit. Statistical significance was determined using t-test.

**Immunocytochemistry**

Cells were fixed with 4% PFA for 15 min, followed by a 0.2% Triton-X-100 permeabilization for 20 min, and blocking with PBS supplemented with 2% BSA for 2 h. Fixed cells were then incubated with a mix of 1:200 rabbit anti-Pdx1 (Abcam) and 1:500
guinea pig anti-insulin (Sigma) overnight at 4 °C. As secondary antibodies, AlexaFluor594 anti-rabbit and AlexaFluor488 (Invitrogen) anti-guinea pig were used. Images were acquired on an ImageXpress Micro automated microscope (Molecular Devices). Exposure settings: 600 ms for Pdx1 (TxRed), 200 ms for insulin (FITC), and 8 ms for DAPI. Statistical significance was determined using t-test.

Gene expression

Total mRNA from siRNA and compound-treated cells were extracted with Qiagen RNeasy Plus Mini Kit. qPCRs were performed with Power SybrGreen PCR Master Mix and an Applied Biosystems 7900HT plate reader. Mouse primers were obtained from IDT and are listed in Table S2 in File S1.

Results

Experimental strategy and rationale

We were interested in comparing the genetic and proteomic levels of various transcription factors in alpha and beta cells, as such proteins are linked with lineage reprogramming. Thus, we compared the gene-expression profiles of the mouse alpha-cell (αTC1) and beta-cell (βTC3) lines (Figure 1A). In parallel, we compared the proteomes and phosphoproteomes of alpha cells and beta cells using stable isotope labeling by amino acids in cell culture (SILAC; Figure 1B) [19–21]. We used a three-state labeling strategy, with two states corresponding to the individual cell populations, and the third state corresponding to a mixed proteome from alpha and beta cells. This approach enabled four protein intensity measurements for alpha cells and beta cells using only two replicates (Figure S2 and S3 in File S1). We analyzed the phosphoproteomes of alpha cells and beta cells by enrichment of phosphopeptides using immobilized metal-affinity chromatography (Figure 1B), and also determined the changes in the phosphoproteome of alpha cells upon treatment with BRD7389 (1 h, 120 h) or GW8510 (120 h) (Figure 1C).

Transcriptome analysis and phenotypic studies

We used previously described gene-expression profiling data [14], where the transcript levels of ~14,000 genes of alpha and beta cells were determined using GeneChip Mouse Genome 430A arrays (Affymetrix). A similar comparison of alpha and beta cell transcriptomes has been reported, using cell sorting of primary human islets [22]. To identify the genes most differentially expressed between alpha cells and beta cells, we used comparative marker selection [23], which employs statistical approaches such as false-discovery rate (FDR) and family-wise error rate (FWER) to account for multiple-hypothesis testing. From these top genes, we identified the transcription factors that were differentially expressed in alpha cells and beta cells (Figure S4 in File S1). A number of transcription factors known to be involved in alpha- and beta-cell specification were identified, including Pdx1, Mnx1, and Inx1. To examine the pathways involved with differentially expressed genes, we used gene-set enrichment analysis (GSEA) [24,25], which determines whether a pre-defined set of genes shows statistically significant, concordant differences between two biological states (Figure 2A, B). We found that, among other gene sets, genes corresponding to oxidative phosphorylation, hypoxia, branched-chain amino acid catabolism, and electron transport were enriched in alpha cells (Figure 2A, Table S3 in File S1). In beta cells, gene sets corresponding to membrane trafficking and antigen presentation and processing were enriched (Figure 2B, Table S4 in File S1).

Since GSEA suggested that the alpha cell line may have a higher metabolic rate than beta cells, we compared the mitochondrial respiration and glycolytic activity in αTC1 cells, BRD7389-treated αTC1 cells, and two beta cell lines: βTC3 and INS-1E cells. We observed higher glycolysis rate, maximum glycolytic capacity, and glycolytic reserve in αTC1 cells, as measured by extracellular acidification rate (Figure 2C, S5 in File S1). We also determined mitochondrial respiration in cell populations by quantifying extracellular oxygen consumption rates (OCR) in the presence of various mitochondrial inhibitors [26]. αTC1 cells had elevated basal respiration rates, energy coupling efficiency, and maximum respiration rate compared to the beta cell lines (Figure 2D). Further, treatment of αTC1 cells with BRD7389 led to a decrease in the overall glycolytic activity and mitochondrial respiration rates, a phenotype reminiscent of the beta cell lines (Figure 2D) [27–30], further supporting the hypothesis that BRD7389 directs alpha cells towards an intermediate cell state.

Proteome and PTM coverage and analysis

We performed quantitative proteomics on the alpha cells, compound-treated alpha cells, and beta cells using SILAC [19–21]. Briefly, cells were cultured in media with amino acids containing light, medium, or heavy isotopes of arginine and lysine. Cell lysates from these three SILAC states were mixed and proteins were reduced, alkylated, and digested with trypsin. The SILAC media (e.g., light, medium, or heavy) from which each observed tryptic peptide originates determines the isotopic label state of the lysine or arginine residue in each peptide. The peptides were subsequently fractionated using strong cation exchange chromatography and phosphopeptides were enriched using immobilized metal-ion chromatography, where phosphopeptides chelate to a bead-immobilized iron (III) complex. Protein ratios were determined from the Protein Groups table generated by the MaxQuant [31,32] software package v1.0.13.13. Two independent SILAC triple-labeling experiments were completed for both the proteome and phosphoproteome analyses of alpha cells and beta cells, with Pearson correlation coefficient r = 0.9 between replicates (Figure S3 in File S1). In total, 3,250 proteins and 9,978

---

Table 1. Summary of proteomic studies.

|                | No. of proteins quantified | No. of proteins ratios with >3-fold change |
|----------------|---------------------------|-------------------------------------------|
| Total proteome | 3250                      | 306                                       |
| pSTY peptides  | 9979*                     | 1056                                      |

*including 467 phosphorylated kinase peptides.

Total proteome results based on 24 SCX fractions over two SILAC experiments. pSTY peptide results are based on 12 SCX fractions over two SILAC experiments.

doi:10.1371/journal.pone.0095194.t001
| Leading Protein ID | Gene | Protein Names                                                                 | β/α (Log2) | p-value |
|-------------------|------|-------------------------------------------------------------------------------|------------|---------|
| IP00228830        | Ube3c| Ubiquitin-protein ligase E3C                                                   | 2.0634     | 0.0051  |
| IP00420577        | Cand2| Cullin-associated NEDD8-dissociated protein 2;Cullin-associated and neddylation-dissociated protein 2; p120 CAND2/TPB-interacting protein of 120 kDa B | 2.7923     | 0.0003  |
| IP00124993        | Eph7 | EPH type A receptor 7;Tyrosine-protein kinase receptor EHK-3                  | 2.0891     | 0.0047  |
| IP00467350        | Pbk  | Lyphokine-activated killer T-cell-originated protein kinase                    | 2.286      | 0.0022  |
| IP00136625        | Nagk | N-acetyl-D-glucosamine kinase; GlcNAc kinase                                   | 2.3244     | 0.0019  |
| IP00222731        | Baiap2| Brain-specific angiogenesis inhibitor 1-associated protein 2;Insulin receptor tyrosine kinase 53 kDa subrate | 2.5636     | 0.0007  |
| IP00119575        | Prkar1a| Putative uncharacterized protein; cAMP-dependent protein kinase type I-alpha regulatory subunit | 4.081      | 0.0000  |
| IP00649296        | Camk2b| Calcium/calmodulin-dependent protein kinase II                                | 4.3953     | 0.0000  |
| IP00465657        | Map3k15| Mitogen-activated protein kinase kinase kinase 15; MAPK/ERK kinase kinase 15 | – 3.3066   | 0.0000  |
| IP00471226        | ABR1| Activator of basal transcription 1                                             | – 1.9123   | 0.0097  |
| IP00928012        | Ptpn2| Protein tyrosine phosphate, receptor type, N polypeptide 2; Receptor-type tyrosine-protein phosphatase N2;PTP IA-2beta; Protein tyrosine phosphate-β | 2.3397     | 0.0018  |
| IP00752710        | Cebpz| CCAAT/enhancer-binding protein zeta/CCAAT-box-binding transcription factor   | – 2.0338   | 0.0064  |
| IP00674690        | Tcf7l3| Transcription factor 25; Nuclear localized protein 1; Nuclear localized protein-1 isoform d | 2.3231     | 0.0019  |
| IP00923679        | Irr2 | Insulin receptor substrate 2/PS                                                | – 2.1428   | 0.0044  |
| IP00222731        | Baiap2| Brain-specific angiogenesis inhibitor 1-associated protein 2;Insulin receptor tyrosine kinase 53 kDa subrate; Insulin receptor substrate p53; Insulin receptor substrate protein of 53 kDa; Brain-specific angiogenesis inhibitor 1-associated protein 2, isoform CRA_c | 2.5636     | 0.0007  |
| IP00132557        | Pdx1 | Pancreas-duodenum homeobox protein 1; Insulin promoter factor 1; Slet/duodenum homeobox 1; Somatostatin-transactivating factor 1 | 2.6903     | 0.0004  |
| IP00471240        | Ins1m| Insulinoma-associated protein 1; Zinc finger protein IA-1                    | 3.9295     | 0.0000  |
| IP00134310        | Ins1 | Insulin-1, Insulin-1 B chain, Insulin-1 A chain                              | 4.4525     | 0.0000  |
| IP00134311        | Ins2 | Insulin-2, Insulin-2 B chain, Insulin-2 A chain                              | 5.1812     | 0.0000  |
| IP00886028        | Igf2 | Insulin-like growth factor II; Multiplication-stimulating polypeptide, IGF-II, Preptin | 6.1304     | 0.0000  |
| IP00135645        | Gcg  | Glucagon                                                                      | – 4.2082   | 0.0000  |
| IP00121190        | Egfr | Epidermal growth factor receptor                                              | – 2.0428   | 0.0062  |
| IP00230133        | Hist1h1b| Histone H1.5, H1 VAR.5, H1b                                                      | – 2.0679   | 0.0057  |
| IP00223713        | Hist1h1c| Histone H1.2, H1 VAR.1, H1c                                                    | – 2.2984   | 0.0024  |
| IP00223714        | Hist1h1e| Histone H1.4, H1 VAR.2, H1e                                                    | – 2.4348   | 0.0014  |
| IP00228616        | Hist1h1a| Histone H1.1, H1 VAR.3                                                        | – 2.4669   | 0.0013  |
| IP00114333        | Rps6ka3| Ribosomal protein S6 kinase alpha-3                                             | 1.8178     | 0.0117  |

Table 2. Proteins with different expression levels in alpha and beta cells.
phosphopeptides were quantified across both biological replicates. Approximately 10% of proteins had greater than a three-fold difference in abundance between alpha and beta cells (Table 1), including known hormones (e.g., insulin, glucagon) and kinases (Table 2). Exploration of role of these proteins may provide further insight into the similarities and differences between alpha and beta cells. Neuropeptide Y and somatostatin, which are known to inhibit insulin secretion, were expressed at higher levels in beta cells compared to that in alpha cells [33–35]. Pdx1 and amylin, which play a key role in several beta-cell functions, were also expressed at higher levels in beta cells. A comparison of the phosphoproteomes of alpha and beta cells revealed interesting differences. For example, while glucagon is expressed at a higher level in alpha cells, the phosphorylation levels at serines 150 and 152 are higher in beta cells. Further, while insulin is expressed at higher levels in beta cells, the level of phosphorylation at threonine 51 is higher in alpha cells. We were able to detect known p38 MAP kinase-mediated phosphorylation of transcription factors MalA and Pdx1 at serine342 and serine 269, respectively [36–38].

The phosphoproteome of alpha cells was not significantly perturbed in the first hour of BRD7398 treatment, as only 2% of phosphopeptides showed alteration in levels. However, after five days of BRD7398 treatment, 9% of phosphopeptides were upregulated and 5% were downregulated. BRD7398 and GW8510 inhibit RSK and CDK2 kinases, respectively. Hence, we expected a decrease in phosphorylation of protein substrates of Rsk and Cdk2 upon BRD7398 or GW8510 treatment of alpha cells. Accordingly, we observed a decrease in S6 and EF2 phosphorylation, known substrates of RSK and CDK2, respectively (Table S5 in File S1).

Suppression of Brsk1 and Camkk2 elicits beta cell features in αTC1 cells

Although several kinases were differentially expressed in alpha and beta cells, we focused our attention on Brsk1 and Camkk2, as they were more highly phosphorylated in alpha cells compared to beta cells, and in untreated alpha cells compared to compound-treated cells (Table S6 in File S1). We were unable to quantify absolute protein levels of these kinases in our proteomic analyses, but gene expression analysis suggested higher mRNA levels of Camkk2 in beta cells. Since the role of these proteins in maintenance of alpha cell state was unknown, we initiated our investigation by performing siRNA-mediated knock-down of Brsk1 or Camkk2 in αTC1 cells, and determined the expression of alpha and beta cell-specific genes. Brsk1 and Camkk2 mRNA levels were reduced by 64% and 85%, respectively, after three-day siRNA transfection (Figure S6 in File S1). Expression of Camkk2 was also reduced in siBrsk1-treated cells (53%), suggesting that Brsk1 may be an upstream activator of Camkk2. Brsk1 knock-down resulted in the upregulation of the mRNA levels of genes important to beta-cell identity, including Pdx1, Ngn3, Nxs2.2, and glucokinase (Gck) (Figure 3A), while Camkk2 down-regulation elicited the expression of Nxs2.2, Pdx1, MafB, and the hormones glucagon (Gcg) and insulin (Ins2) (Figure 3B). Modest levels of Pdx1 protein expression were detected by immunofluorescence in siBrsk1- and siCamkk2-treated cells (Figure S6 in File S1). Consistent with these observations, STO-609, a Camkk antagonist, and KN93 and KN93, two selective Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitors, also increased Pdx1 protein expression in αTC1 cells (Figure 3C).

Since PDX1 protein levels after 3 days of gene knock-down were detectable but faint, we performed a 10-day knock-down of Brsk1, Camkk2, and Skl1, an upstream modulator of Brsk1, using lentiviral shRNAs (Figure 4). When using hairpins targeting Brsk1 and Camkk2, a decrease in these kinases corresponded to a concomitant increase in Pdx1 mRNA expression (Figure 4A–B). Hairpins targeting Skl1 (two out of three) also increased Pdx1 expression (Figure 4C). The fact that not all hairpins had the same effect might reflect off-target silencing effects of these hairpins, which are part of the limitations of using small-interfering RNAs.
Moreover, individual hairpins to Camkk2, Brsk1, and Stk11 elicited the expression of Pdx1 protein, as detected by immunofluorescence (Figure 4D–S). PDX1-positive cells also co-stained for insulin when Brsk1 or Camkk2 were knocked down, and more modestly with knock-down of Stk11 (Figure 4 I,M,Q). Taken together, our results suggest a role for CAMK family proteins in maintaining an alpha-cell phenotype.

Discussion

In this study, we compared the transcriptomes, proteomes, and phosphoproteomes of a pancreatic alpha and beta cell line, with the aim of identifying new targets whose perturbation may induce expression of beta-cell markers in alpha cells. Gene-expression analysis suggested enhanced mitochondrial respiration and glycolysis in alpha cells compared to beta cells, which we confirmed experimentally. Furthermore, BRD7389 treatment of alphaTC1 lowered mitochondrial respiration and glycolytic activity as

Figure 4. Longer-term lentiviral knockdown of Brsk1 and Camkk2 stimulates PDX1 and insulin protein expression in alphaTC1 cells. Cells were infected with lentivirus carrying expression cassettes that encode shRNAs against (A) Brsk1, (B) Camkk2, (C) Stk11, and were selected with puromycin for 10 days. Pdx1 mRNA expression (white bars) was measured jointly with the expression of each of the shRNA-targeted genes (black bars). Data represent fold change (in log2 scale), compared to the average of control empty vectors. Data represent mean and standard deviation of four independent experiments. The significance was determined by t-test. *p<0.05 and **p<0.01. (D–S) Nuclei (blue), insulin (green), and Pdx1 (red) immunofluorescence, and merged images in 10-day shRNA-expressing alphaTC1 cells: (D–G) control virus, (H–K) sh1_Camkk2, (L–O) sh1_Brsk1, (P–S) sh1_Stk11. Scale bar = 100 μm.

doi:10.1371/journal.pone.0095194.g004
these cells progressed towards a state intermediate between alpha and beta cells. Beta cell lines, in particular INS-1E, have been reported to have high proton leak through the mitochondrial membrane [27], and to have strongly reduced lactate production [28–30], which is consistent with our observed low spare respiration and glycolytic capacity. The observed differences in the mitochondrial respiration and glycolytic activity could also arise from differences in the growth rate of the alpha and beta cell lines. Indeed, the beta cell lines used herein have a lower growth rate (doubling time: 2–3 days) compared to that of αTC1 cells (doubling time: 1–2 days).

Most lineage-reprogramming efforts involve overexpression of transcription factors that occur at higher levels in the target cell type. We have identified several transcription factors that are enriched in alpha cells and beta cells in our microarray data. Expected genes were readily identified; for example, Pdx1 plays an important role in beta cell maturation and function [40]. Interestingly, one of the identified transcription factors, motor neuron and pancreas homeobox 1 (Mnx1), was recently reported to play an important role in cell fate determination in zebrafish [41]. Physiological differences between alpha and beta cells are also reflected in the annotated gene sets enriched in these cells. Genes involved in respiration and branched-chain amino acid metabolism were enriched in alpha cells, while the genes associated with membrane trafficking and lysosomes were enriched in beta cells, pointing to the relative importance of these biological processes in the two cell types.

Our prior studies suggested that the inhibition of specific kinases in alpha cells can lead to expression of key markers of beta cells [12,13]. Here, we identified two kinases whose knock-down induced beta-cell markers in alpha cells. BRSK1, also known as SAD-B, is a serine/threonine kinase strongly expressed in mammalian forebrain to determine neuronal polarization [42]. BRSK1 is activated both in vitro and in vivo by serine/threonine-protein kinase 11 (STK11), also known as liver kinase B1 (LKB1), which plays an important role in the polarization of cortical axons [43–45]. STK11 is in turn a tumor suppressor and regulator of energy homeostasis through the activation of AMP-activated protein kinase (AMPK) [46]. A beta cell-specific deletion of Stk11 causes an increase in beta cell-mass and insulin secretion, effects mediated by an activation of the mTOR pathway [47]. In combination with STK11, CAMKK2 (Camkkβ) phosphorylates and activates AMPK [48,49], while in combination with CAMKK1 (Camkkδ), it phosphorylates and activates CAMK1 and CAMK4 [50]. Camkk2 null mice are protected from obesity, insulin resistance, and glucose intolerance [51]. It is noteworthy that downregulation of Camkk2 in alpha cells increases the expression of both insulin and glucagon. Directed differentiation of embryonic stem cells into mature hormone secreting endocrine cells, and understanding the signaling role of their phosphorylated forms. We anticipate that such studies may spur development of small molecules for lineage reprogramming of alpha cells to insulin-producing cells.

Supporting Information

**File S1** Six supplementary figures (Figures S1–S6) and six supplementary tables (Tables S1–S6).

**File S2** Phosphoproteomic data for compound treatments.

**File S3** Phosphoproteomic data comparing αTC and βTC cells.

**File S4** Total proteomic data comparing αTC and βTC cells.

Acknowledgments

We thank Dr. Mukta Bagul and Will Harrington, investigators at the siRNA platform at the Broad Institute, for their fruitful discussions and guidance while conducting lentiviral shRNA experiments. S.L.S. is a Howard Hughes Medical Institute Investigator.

Author Contributions

Conceived and designed the experiments: DFY SK SLS BKW. Performed the experiments: AC KH PM NU DFY SK. Analyzed the data: AC PM NU PD PAC SLS SC BKW. Contributed reagents/materials/analysis tools: PM NU PD. Wrote the paper: AC KH BKW.

References

1. Gepts W (1965) Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14: 619–633.
2. van Belle TL, Coppieters KT, van Herrath MG (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91: 79–118.
3. Hirsch IB, Farkas-Hirsch R, Skyler JS (1990) Intensive insulin therapy for type 1 diabetes: long-term outcome and cost-effectiveness. N Engl J Med 322: 1232–1240.
4. Rajab A (2010) Ilet transplantation: alternative sites. Curr Diab Rep 10: 332–337.
5. de Kort H, de Koning EJ, Rabelink TJ, Brujin JA, Bajema IM (2011) Ilet transplantation in type 1 diabetes. BMJ 342: d217.
6. Chatenoud L (2008) Chemical immunosuppression in islet transplantation—friend or foe? N Engl J Med 358: 1192–1193.
7. Johnson JD, Aot Z, Apo P, Li H, Dai L, et al. (2009) Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant 18: 835–845.
31. Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26: 1367–1372.

32. Skoglund G, Gross K, Ahren B, Lusahanires-Mariami M-M (1993) Different mechanisms are involved in neuropeptide YY-induced pancreatic vasoconstriction and inhibition of insulin secretion. Eur Jour Pharm 236: 69–74.

33. Molz JH, McDonald JK (1983) Neuroepitope Y: Direct and indirect action on insulin secretion in the rat. Peptides 6: 1155–1159.

34. Stroswizki MZ, Parmar RM, Blake AD, Schaffner JM (2000) Somatostatin Inhibits Insulin and Glucagon Secretion via Two Receptor Subtypes: An In Vitro Study of Pancreatic Islands from Somatostatin Receptor 2 Knockout Mice. Endocrinology 141: 111–117.

35. Zhou G, Wang H, Liu S-H, Shali KM, Lin X, et al. (2013) p38 MAP kinase interacts with and stabilizes pancreatic and duodenal homeobox-1. Curr Mol Med 13: 377–386.

36. Guo S, Vanderford NL, Stein R (2010) Phosphorylation within the MaNa Termius Regulates C-terminal Dimerization and DNA Binding. J Biol Chem 285: 12653–12661.

37. Sifi-Felice K, Pouponnot C, Gillet S, Lecon I, Girault J-A, et al. (2005) MaNa transcription factor is phosphorylated by p38 MAP kinase. FEBS Lett 579: 3347–3354.

38. Bora RS, Gupta D, Mukkur TK, Saini KS (2012) RNA interference therapeutics for cancer: challenges and opportunities (review). Mol Med Report 6: 9–15.

39. Iype T, Francis J, Garvey JC, Schuler JC, Neshur R, et al. (2005) Mechanism of insulin gene regulation by the pancreatic transcription factor Pdx-1: application of pre-mRNA analysis and chromatin immunoprecipitation to assess formation of functional transcriptional complexes. J Biol Chem 280: 16798–16807.

40. Dalgin G, Ward AB, Hao LT, Beattie CE, Nechiporuk A, et al. (2011) Zebrafish mnx1 controls cell fate choice in the developing endocrine pancreas. Development 138: 4597–4608.

41. Kishi M, Pan YA, Crump JG, Sanes JR (2005) Mammalian SAD kinases are required for neuronal polarization. Science 307: 929–932.

42. Anderson KA, Ribar TJ, Lin F, Noellier PK, Green MF, et al. (2008) Calmodulin-dependent protein kinase-beta is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23: 833–843.

43. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeuetic effects of metformin. Science 310: 1642–1646.

44. Fu A, Ng AC, Depatie C, Wijesekara N, He Y, et al. (2009) Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice. Cell Metab 10: 285–295.

45. Woods A, Dickerson K, Heath R, Hong SP, Monicillove M, et al. (2005) Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2: 21–33.

46. Havelvy SA, Pan DA, Mustard KJ, Ross L, Baim J, et al. (2005) Calmodulin-dependent protein kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2: 9–19.

47. Soderling TR (1999) The Ca-calmodulin-dependent protein kinase cascade. Trends Biochem Sci 24: 232–236.

48. Anderson KA, Ribar TJ, Lin F, Noellier PK, Green MF, et al. (2008) Hypothalamic CaMKII2 contributes to the regulation of energy balance. Cell Metab 7: 377–388.

49. Cao W, Sohail M, Kourbanagia GA, Lobo VG, et al. (2011) Differential effects of PKA-controlled CaMKII2 variants on neuronal differentiation. RNA Biol 8: 1061–1072.

50. Cary RL, Waddell S, Racioppi Li, Long F, Novack DV, et al. (2013) Inhibition of Ca2+/calmodulin-dependent Protein Kinase Kinase 2 Stimulates Osteoblast Formation and Inhibits Osteoclast Differentiation. J Bone Miner Res 28: 1599–1610.